Irinotecan Liposome Combined With Anlotinib as Second-line Regimen for SCLC

Clinical trial NCT06258642 · RECRUITING

Trial details

NCT number: NCT06258642
Sponsor: Fudan University
Status: RECRUITING
Phase: Not Applicable
Study type: INTERVENTIONAL

Small Cell Lung Cancer Recurrent

Start date: 2024-04-17
Primary completion: 2026-04-30
Enrollment: 39

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.